This white paper discusses the strategy to create an integrated and innovative program capable of demonstrating the “value” of a therapy for scleroderma, as well as clinical utility and therapeutic novelty.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
